55 results
8-K
EX-99.1
ITCI
Intra-Cellular Therapies Inc
18 Jun 24
Other Events
7:37am
in patients who are vulnerable to hypotension.
Falls. CAPLYTA may cause sleepiness or dizziness and can slow thinking and motor skills, which may lead
8-K
EX-99.1
ITCI
Intra-Cellular Therapies Inc
7 May 24
Intra-cellular Therapies Reports First Quarter 2024 Financial Results
7:40am
who are vulnerable to hypotension.
Falls. CAPLYTA may cause sleepiness or dizziness and can slow thinking and motor skills, which may lead to falls
8-K
EX-99.1
ITCI
Intra-Cellular Therapies Inc
16 Apr 24
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
7:10am
are vulnerable to hypotension.
Falls. CAPLYTA may cause sleepiness or dizziness and can slow thinking and motor skills, which may lead to falls
8-K
EX-99.1
ITCI
Intra-Cellular Therapies Inc
22 Feb 24
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Corporate Update
7:39am
or dizziness and can slow thinking and motor skills, which may lead to falls and, consequently, fractures and other injuries. Patients should
8-K
EX-99.1
298 bsjh38zm
2 Nov 23
Intra-cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
8:01am
8-K
EX-99.1
ryu zv6kzd
3 Aug 23
Intra-cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
7:39am
8-K
EX-99.1
p5cxum4
4 May 23
Intra-cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
m29iz6y3drlq60shg
3 Nov 22
Intra-cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:35am
8-K
EX-99.1
aiabkj7cso
9 Aug 22
Intra-cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
7:38am
8-K
EX-99.1
hbczgg5t q5cugw
10 May 22
Intra-cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
ftqd6su 9bd8h
25 Apr 22
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations
7:12am
8-K
EX-99.1
isz34jjzu52
1 Mar 22
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2021 Financial Results and Provides Corporate Update
7:49am
8-K
EX-99.1
1obxufr 3wxgdq17hexz
20 Dec 21
Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults
7:04am
8-K
EX-99.1
9q72ovo8ieme
9 Nov 21
Intra-cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
7:49am
8-K
EX-99.1
6wp88
9 Aug 21
Intra-cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
ilii6zltd5rlzumn
10 May 21
Intra-cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update
7:37am